logo

Vbi Vaccines Inc. (VBIV)



Trade VBIV now with
  Date
  Headline
2/25/2019 8:12:22 AM VBI Vaccines Q4 Revenue Rises To $2.7 Mln From $0.2 Mln Prior Year
12/20/2018 8:11:39 AM VBI Vaccines Announces Phase 2 Clinical Study Design Of Its Prophylactic CMV Vaccine Candidate
12/13/2018 9:11:14 AM VBI Vaccines Prices Underwritten Public Offering Of 26.80 Mln Shares At US$1.40/shr
12/12/2018 4:03:08 PM VBI Vaccines Announces Proposed Public Offering Of Common Shares
12/6/2018 8:11:33 AM VBI Vaccines Signs License, Collaboration Deal With Brii Biosciences To Develop Functional Cure For Hepatitis B
11/9/2018 7:14:17 AM VBI Vaccines Q3 Net Loss $15.4 Mln Or $0.24/Shr Vs Loss $9.8 Mln Or $0.24/Shr Last Year
9/25/2018 8:03:45 AM VBI Vaccines Announces Second Positive DSMB Review In Phase 1/2a Study Of VBI-1901 In Recurrent Glioblastoma Patients
8/15/2018 8:06:02 AM VBI Vaccines Appoints Christopher McNulty As CFO And Head Of Business Development
7/26/2018 7:28:09 AM VBI Vaccines Q2 Net Loss $16.7 Mln, Revenue $0.2 Mln
5/10/2018 7:36:40 AM VBI Vaccines Reports Positive Final Top-line Results From Phase 1 Study Of VBI-1501
5/1/2018 8:06:44 AM VBI Vaccines Q1 Net Loss $12.3 Mln Or $0.19 Per Share
4/19/2018 8:08:49 AM VBI Vaccines Completes Enrollment In PROTECT Phase 3 Clinical Study For Sci-B-Vac® Hepatitis B Vaccine
4/17/2018 8:02:55 AM VBI Vaccines Announces Positive DSMB Review In Phase 1/2a Study Of VBI-1901 In Recurrent Glioblastoma (GBM) Patients